Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.